Safety Study of MGD009 in B7-H3-expressing Tumors

Summary

The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely. Assessments will be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics (PD) and to evaluate potential anti-tumor activity of MGD009.

Timeline

Start

2015-09

Primary completion

2019-11-25

Completion

2019-11-25

Drugs

Indications